ClinicalTrials.gg
CompletedNCT02143973Updated May 21, 2025Results posted

Open Label Extension Study of Nalbuphine HCl ER in Hemodialysis Patients With Uremic Pruritus

A Phase 2/3 interventional study of nalbuphine HCl ER in Uremic Pruritus and Pruritus, sponsored by Trevi Therapeutics. Completed at 35 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-05-21.

Sponsored by Trevi Therapeutics · Phase 2/3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
167
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 163 studies in Pruritus with a site in United States — 24 open to participants now, 28 under way, 8 of them phase 3. Pruritus · United States.

Enrollment
51st of 153
167 · median 70
Started
2014
with 8 others
Phase 2/3
5 of 163
none open now
Registered
44th of 163
by date

Among the 163 studies in Pruritus with a site in United States, this one is the 51st largest by enrollment of the 153 interventional ones that give a count, is one of 9 that started in 2014, is one of 5 in phase 2/3, and was the 44th registered.

Pruritus

491 studies on the registry are indexed under Pruritus; 94 are open to participants now.

Browse Pruritus studies →

Open to participants now

24 of the 163 studies in Pruritus with a site in United States are open now. Recruiting first, the newest first:

19 more — sign in →

All 24 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 54 Pruritus studies recruiting now, 22 (41%) set no upper age limit and 24 (44%) stop at 75 or younger; 15 take children under 18; 10 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 163 studies in Pruritus with a site in United States, or all of them as a file.
02

Study summary

The primary objective of the study is to evaluate the overall safety of nalbuphine HCL ER tablets during a treatment period of up to 24 weeks.

03

Conditions studied

  • Uremic Pruritus
  • Pruritus

Browse trials for

Keywords

  • Uremic
  • Pruritus
  • Itch
  • Chronic Itch
  • Nalbuphine
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject completed participation in the TR02 study
  • Subject is currently receiving in-center hemodialysis at the time of consent

Exclusion criteria

Exclusion Criteria:

  • Subject receiving or anticipated to be receiving nocturnal dialysis or home hemodialysis treatment during the study
  • Subject received opiates on a daily basis during the 1 week prior to screening
  • Other than the TR02 Study Drug, Subject received any drug within 4 weeks prior to Screening
  • Subject is a pregnant or lactating female
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
167 participants (actual)

Study arms

  • Experimental
    nalbuphine HCl ER

    nalbuphine HCl ER titrated from a dose of 30 mg QD to 120 BID for up to 3 weeks based on tolerability and efficacy, then maintained for an additional 21 weeks. Total duration of 24 weeks.

    Drug: nalbuphine HCl ER

Interventions

06

What researchers measure

Primary outcomes

  1. Number and Percetage of Participants With Treatment Emergent Adverse Events (TEAEs)

    The number of participants reporting at least one TEAE of a particular body system and preferred term are reported (incidence)

    Time frame: 24 weeks

07

Results

Posted Sep 7, 2020

Participant flow

Participant flow — Overall Study
MilestoneNalbuphine HCl ER
Started167
Completed101
Not completed66

Outcome measures

PrimaryNumber and Percetage of Participants With Treatment Emergent Adverse Events (TEAEs)

The number of participants reporting at least one TEAE of a particular body system and preferred term are reported (incidence)

Time frame:
24 weeks
Reported as:
Count of participants · Participants
Number and Percetage of Participants With Treatment Emergent Adverse Events (TEAEs)
ParticipantsNalbuphine HCl ER
Number and Percetage of Participants With Treatment Emergent Adverse Events (TEAEs)133

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Nalbuphine HCl ER0/167 (0%)54/167 (32.3%)0/167 (0%)
Most frequent serious events
Showing 10 of 68
Most frequent serious events
EventNalbuphine HCl ER
Arteriovenous graft site infectionInfections and infestations4/167
Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders4/167
Non-cardiac chest painGeneral disorders4/167
SepsisInfections and infestations3/167
HypotensionVascular disorders3/167
DiverticulitisInfections and infestations2/167
PneumoniaInfections and infestations2/167
Septic shockInfections and infestations2/167
SyncopeNervous system disorders2/167
Acute pulmonary oedemaRespiratory, thoracic and mediastinal disorders2/167

Baseline characteristics

Age, Continuous
Age, Continuous(years)Nalbuphine HCl ER
Mean53.1 ± 12.2
Sex: Female, Male
Sex: Female, Male(Participants)Nalbuphine HCl ER
Female75
Male92
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Nalbuphine HCl ER
Hispanic or Latino31
Not Hispanic or Latino136
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Nalbuphine HCl ER
American Indian or Alaska Native2
Asian1
Native Hawaiian or Other Pacific Islander1
Black or African American89
White73
More than one race1
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(participants)Nalbuphine HCl ER
United States146
Europe21
08

Study locations

35 sites
  • Nephrology Associates PC
    Birmingham, Alabama 35211, United States
  • University South Alabama Medical Center
    Mobile, Alabama 36617, United States
  • Arizona Kidney Disease and Hypertension Center
    Phoenix, Arizona 85012, United States
  • U.S. Renal Care Inc.
    Pine Bluff, Arkansas 71603, United States
  • North America Research Institute
    Azusa, California 91702, United States
  • Pegasus Dialysis Center
    Bakersfield, California 93308, United States
  • Central Nephrology Medical Group
    Bakersfield, California 93309, United States
  • Mark Lee MD, Inc
    Whittier, California 90606, United States
  • Nephrology and Hypertension Associates PC
    Middlebury, Connecticut 06762, United States
  • Pines Clinical Research
    Pembroke Pines, Florida 33025, United States
  • Genesis Clinical Research
    Tampa, Florida 33614, United States
  • DaVita Central Orlando Dialysis
    Winter Park, Florida 32789, United States
  • Southwest Georgia Nephrology Clinic PC
    Albany, Georgia 31701, United States
  • Renal Physicians of Georgia
    Macon, Georgia 31217, United States
  • Pacific Renal Research Institute
    Meridian, Idaho 83642, United States
  • Fresenius Medical Care of Evergreen Park
    Evergreen Park, Illinois 60805, United States
  • Western New England Renal and Transplant Association
    Springfield, Massachusetts 01107, United States
  • Nephrology Center DBA Paragon Health
    Kalamazoo, Michigan 49007, United States
  • McComb Limited Care Facility
    McComb, Mississippi 39648, United States
  • Kidney Associates of Kansas City PC
    Kansas City, Missouri 64131, United States
  • Nephrology-Hypertension Associates of Central New Jersey PA
    North Brunswick, New Jersey 80902, United States
  • Renal Medicine Associates
    Albuquerque, New Mexico 87109, United States
  • Newtown Dialysis Center Inc
    Astoria, New York 11102, United States
  • Durham Nephrology Associates
    Durham, North Carolina 27704, United States
  • Wake Nephrology Associates PA
    Raleigh, North Carolina 27609, United States
  • Brookview Hills Research Associates LLC
    Winston-Salem, North Carolina 27103, United States
  • University of Cincinnati
    Cincinnati, Ohio 45267, United States
  • Nephrology Research Consortium
    Bethlehem, Pennsylvania 18017, United States
  • Delaware Valley Nephrology
    Philadelphia, Pennsylvania 19118, United States
  • Dialysis Clinic, Inc.
    Philadelphia, Pennsylvania 19140, United States
  • Carolina Diabetes and Kidney Center
    Sumter, South Carolina 29150, United States
  • SouthEast Renal Research Institute
    Chattanooga, Tennessee 37408, United States
  • U.S. Renal Care, Inc.
    Fort Worth, Texas 76105, United States
  • U.S. Renal Care Inc.
    Fort Worth, Texas 76164, United States
  • U.S. Renal Care Inc
    Mansfield, Texas 76063, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2014, a primary completion of Jan 2016 and a completion of Jan 2016. It does not say whether these dates are actual or estimated.

Results were first posted in Sep 2020, 4 years 8 months after primary completion. A results delay was requested in May 2017.

How these figures are worked out, and which studies are left out of them.

Registered
May 19, 2014
First posted
May 21, 2014
Start
Sep 2014
Primary completionActual
Jan 2016
CompletionActual
Jan 2016
Results delay requested
May 25, 2017
Results first posted
Sep 7, 2020
Last update
May 21, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 21, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02143973
Lead sponsor
Trevi Therapeutics
Responsible party
Sponsor
First posted
May 21, 2014
Start date
Sep 2014
Primary completion
Jan 2016
Completion
Jan 2016
Results posted
Sep 7, 2020
Last update
May 21, 2025

Study contacts

Chief Development Officer
study director · Trevi Therapeutics

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nalbuphine

Start the discussion